Literature DB >> 12900755

T-cell activation by recombinant immunoreceptors: impact of the intracellular signalling domain on the stability of receptor expression and antigen-specific activation of grafted T cells.

C Heuser1, A Hombach, C Lösch, K Manista, H Abken.   

Abstract

Recombinant immunoreceptors are modularily composed of extracellular antigen binding and intracellular signalling domains that are preferentially derived from CD3zeta or Fc epsilon RIgamma. The impact of the signalling domain on the stability of immunoreceptor expression and function is not completely understood. To address this issue, we generated and expressed a panel of recombinant zeta- and gamma-chain immunoreceptors, respectively, in human peripheral blood T cells. The expression level of zeta-chain immunoreceptors in human T cells is significantly lower than those of the homologous gamma-chain receptors. Low zeta-chain receptor expression in peripheral T cells is because of the intracellular signalling domain and independent of the Fc epsilon RIgamma or CD3zeta transmembrane region. Expression of both receptors decreases upon prolonged cultivation. Shortly after receptor engraftment, target cell lysis and induction of IFN-gamma secretion are mediated with similar efficiency by zeta- and gamma-chain immunoreceptors. Upon prolonged propagation, however, T-cell activation mediated by zeta-chain immunoreceptors is more efficient than by gamma-chain receptors, indicating that the initial high expression level of gamma-chain immunoreceptors compensates its lower activation capacity. Consequently, gamma-chain immunoreceptors exhibit a higher threshold value for specific activation and are more pronouncedly inhibited by soluble ligand antigen compared to the homologous zeta-chain receptor. These findings have substantial consequences for the design of recombinant immunoreceptors for use in adoptive immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12900755     DOI: 10.1038/sj.gt.3302023

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  18 in total

Review 1.  Applications of molecular engineering in T-cell-based immunotherapies.

Authors:  David A McBride; Matthew D Kerr; Shinya L Wai; Nisarg J Shah
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2019-04-10

2.  A recombinant anti-carcinoembryonic antigen immunoreceptor with combined CD3zeta-CD28 signalling targets T cells from colorectal cancer patients against their tumour cells.

Authors:  A Hombach; C Schlimper; E Sievers; S Frank; H H Schild; T Sauerbruch; I G H Schmidt-Wolf; H Abken
Journal:  Gut       Date:  2005-09-27       Impact factor: 23.059

3.  T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo.

Authors:  Claudia Geldres; Barbara Savoldo; Valentina Hoyos; Ignazio Caruana; Ming Zhang; Eric Yvon; Michele Del Vecchio; Chad J Creighton; Michael Ittmann; Soldano Ferrone; Gianpietro Dotti
Journal:  Clin Cancer Res       Date:  2013-12-13       Impact factor: 12.531

Review 4.  CAR T Cell Therapy for Hematological Malignancies.

Authors:  Xin Yang; Gao-Xiang Wang; Jian-Feng Zhou
Journal:  Curr Med Sci       Date:  2019-12-16

5.  IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo.

Authors:  Mythili Koneru; Terence J Purdon; David Spriggs; Susmith Koneru; Renier J Brentjens
Journal:  Oncoimmunology       Date:  2015-01-23       Impact factor: 8.110

Review 6.  Chimeric antigen receptor-engineered T cells for immunotherapy of cancer.

Authors:  Marc Cartellieri; Michael Bachmann; Anja Feldmann; Claudia Bippes; Slava Stamova; Rebekka Wehner; Achim Temme; Marc Schmitz
Journal:  J Biomed Biotechnol       Date:  2010-05-05

Review 7.  Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions.

Authors:  Kevin J Curran; Hollie J Pegram; Renier J Brentjens
Journal:  J Gene Med       Date:  2012-06       Impact factor: 4.152

8.  CD3ζ-based chimeric antigen receptors mediate T cell activation via cis- and trans-signalling mechanisms: implications for optimization of receptor structure for adoptive cell therapy.

Authors:  J S Bridgeman; K Ladell; V E Sheard; K Miners; R E Hawkins; D A Price; D E Gilham
Journal:  Clin Exp Immunol       Date:  2014-02       Impact factor: 4.330

Review 9.  Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects.

Authors:  Huan Shi; Meili Sun; Lin Liu; Zhehai Wang
Journal:  Mol Cancer       Date:  2014-09-21       Impact factor: 27.401

10.  Enhancement of antitumor activity by using a fully human gene encoding a single-chain fragmented antibody specific for carcinoembryonic antigen.

Authors:  Hirotomo Shibaguchi; Naixiang Luo; Naoto Shirasu; Motomu Kuroki; Masahide Kuroki
Journal:  Onco Targets Ther       Date:  2017-08-22       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.